Fate Therapeutics Management

Management criteria checks 3/4

Fate Therapeutics' CEO is J. Wolchko, appointed in Dec 2015, has a tenure of 8.33 years. total yearly compensation is $8.15M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth €973.20K. The average tenure of the management team and the board of directors is 6.3 years and 13.2 years respectively.

Key information

J. Wolchko

Chief executive officer

US$8.1m

Total compensation

CEO salary percentage	7.9%
CEO tenure	8.3yrs
CEO ownership	0.2%
Management average tenure	6.3yrs
Board average tenure	13.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has J. Wolchko's remuneration changed compared to Fate Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$161m
Sep 30 2023	n/a	n/a	-US$173m
Jun 30 2023	n/a	n/a	-US$212m
Mar 31 2023	n/a	n/a	-US$235m
Dec 31 2022	US$8m	US$645k	-US$282m
Sep 30 2022	n/a	n/a	-US$294m
Jun 30 2022	n/a	n/a	-US$254m
Mar 31 2022	n/a	n/a	-US$233m
Dec 31 2021	US$12m	US$610k	-US$212m
Sep 30 2021	n/a	n/a	-US$197m
Jun 30 2021	n/a	n/a	-US$212m
Mar 31 2021	n/a	n/a	-US$185m
Dec 31 2020	US$6m	US$570k	-US$173m
Sep 30 2020	n/a	n/a	-US$149m
Jun 30 2020	n/a	n/a	-US$117m
Mar 31 2020	n/a	n/a	-US$112m
Dec 31 2019	US$11m	US$540k	-US$98m
Sep 30 2019	n/a	n/a	-US$86m
Jun 30 2019	n/a	n/a	-US$76m
Mar 31 2019	n/a	n/a	-US$72m
Dec 31 2018	US$4m	US$516k	-US$67m
Sep 30 2018	n/a	n/a	-US$63m
Jun 30 2018	n/a	n/a	-US$57m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$1m	US$480k	-US$43m

Compensation vs Market: J.'s total compensation ($USD8.15M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.

CEO

J. Wolchko (53 yo)

8.3yrs

Tenure

US$8,145,000

Compensation

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
J. Wolchko	Founder	8.3yrs	US$8.15m	0.24% $ 973.2k
Edward Dulac	Chief Financial Officer	3.7yrs	US$3.16m	0.0095% $ 38.3k
Cindy Tahl	General Counsel	8.5yrs	US$3.16m	0.053% $ 214.0k
Bahram Valamehr	Chief Research & Development Officer	6.3yrs	US$3.16m	0.067% $ 269.8k
Jim Beitel	Senior Vice President of Corporate Development	6.6yrs	no data	no data
Jerome Bressi	Senior Vice President of Regulatory & Quality	2.3yrs	no data	no data
Barbara Hickingbottom	Senior VP of Clinical Development	less than a year	no data	no data

6.3yrs

Average Tenure

48.5yo

Average Age

Experienced Management: F6T's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
J. Wolchko	Founder	8.5yrs	US$8.15m	0.24% $ 973.2k
William Rastetter	Independent Chairman	12.4yrs	US$485.59k	0.54% $ 2.2m
John Mendlein	Independent Vice Chairman of the Board	16yrs	US$461.09k	0.27% $ 1.1m
Robert Langer	Member of Scientific Advisory Board	no data	no data	no data
Bennett Shapiro	Member of Scientific Advisory Board	no data	no data	no data
Robert Epstein	Independent Director	10.1yrs	US$460.59k	0.010% $ 40.3k
Stuart Orkin	Member of Scientific Advisory Board	13.9yrs	no data	no data
Sui Huang	Member of Scientific Advisory Board	13.9yrs	no data	no data
Timothy Coughlin	Independent Director	10.7yrs	US$464.09k	0.058% $ 235.5k
Sean Morrison	Member of Scientific Advisory Board	13.9yrs	no data	no data
Mark Krasnow	Member of Scientific Advisory Board	13.9yrs	no data	no data
Karin Jooss	Independent Director	5.1yrs	US$455.09k	0.0086% $ 35.0k

13.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: F6T's board of directors are seasoned and experienced ( 13.2 years average tenure).

Fate Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Founder recently sold €58k worth of stock

Yu-Waye (Wayne) Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023

Founder recently sold €224k worth of stock

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Insufficient new directors

Recent updates

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $79.999997 million.

New minor risk - Shareholder dilution

Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$1.64 loss per share (vs US$2.91 loss in FY 2022)

Fate Therapeutics, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Founder recently sold €58k worth of stock

Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.86 loss in 3Q 2022)

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.79 loss in 2Q 2022)

Fate Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Yu-Waye (Wayne) Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.68 loss in 1Q 2022)

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.91 loss per share (vs US$2.24 loss in FY 2021)

Fate Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued after recent price drop

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold €224k worth of stock

Now 42% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy

Insufficient new directors

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$0.45 loss in 3Q 2021)

Chief Financial Officer recently sold €151k worth of stock

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

Second quarter 2022 earnings released: US$0.79 loss per share (vs US$0.58 loss in 2Q 2021)

Chief Technical Officer recently sold €89k worth of stock

Fate Therapeutics, Inc. Appoints Brian T. Powl as Chief Commercial Officer

First quarter 2022 earnings released: US$0.68 loss per share (vs US$0.48 loss in 1Q 2021)

Insufficient new directors

Fate Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Chief Medical Officer recently sold €133k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Founder recently sold €624k worth of stock

Fate Therapeutics Announces FDA Clearance for Ft536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.68 loss in 3Q 2020)

CFO & Principal Accounting Officer recently sold €262k worth of stock

Fate Therapeutics, Inc. Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-Shelf

Second quarter 2021 earnings released: US$0.58 loss per share (vs US$0.35 loss in 2Q 2020)

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy

Chief Scientific Officer Daniel Shoemaker has left the company

Fate Therapeutics Highlights Positive Interim Data from Its Phase 1 Study of Ft516 in Combination with Rituximab for B-Cell Lymphoma At 2021 Asco Annual Meeting

Fate Therapeutics, Inc. Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia

First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)

Insider recently sold €228k worth of stock

New 90-day low: €69.00

Full year 2020 earnings released: US$2.11 loss per share (vs US$1.44 loss in FY 2019)

Revenue beats expectations

Founder recently sold €6.6m worth of stock

New 90-day high: €93.00

New 90-day high: €83.00

Fate Therapeutics, Inc. Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-Cell Lymphoma

New 90-day high: €57.00

Fate Therapeutics Reports Positive Interim Data from Its Phase 1 Study of FT516 in Combination with Rituximab for B-Cell Lymphoma

Third quarter 2020 earnings released: US$0.68 loss per share

Revenue beats expectations

New 90-day high: €43.00

New 90-day high: €33.80

New 90-day low - €25.80

First half earnings released

CEO Compensation Analysis